explore -WSS

explore

author：hotspot 2025-10-01 22:39:22 - browse：36294

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： How neuroscience research could help beat back brain cancer

hotspot

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Abbott's new stent may help patients with peripheral artery disease

Sarepta Duchenne therapy fails to meet primary endpoint in trial

As H5N1 spreads in cows, experts warn against drinking raw milk

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

How to convince healthy people to buy insurance

hotspot

explore

leisure time

Supreme Court strikes down use of affirmative action

The White House hikes tariffs on plastic syringes made in China

DIEP, the 'gold standard' of breast reconstruction, is under threat

What a koala virus tells us about the human genome

Cancer drug shortages should be causing more outrage

Humans aren't the only ones with an imagination. Rats have it too

New air purifier tech could be key to improving indoor air quality

Travis Kelce and the trap of celebrity vaccine endorsements

Trump demands the U.S. pay no more for drugs than other countries … again

Boston hospital trains restaurant workers on naloxone for overdoses

hotspot

Cherokee Nation medical school graduates its first class

All of Us, NIH's precision medicine initiative, gets a big boost

CVS is willing to dump 10% of its Medicare Advantage members

CVS is willing to dump 10% of its Medicare Advantage members

Sarepta Duchenne therapy fails to meet primary endpoint in trial

After Sarepta trial failure, Duchenne families brace for more debate

entertainment

hotspot

leisure time

focus